title: Simple, reliable and fast spectrofluorometric method for determination of plasma Verteporfin (Visudyne) levels during photodynamic therapy for choroidal neovascularization.
abstract: Photodynamic therapy with Verteporfin, a potent photosensitizer dye, is a very effective treatment for age related macular degeneration due to choroidal neovascularization. Photodynamic therapy offers the potential for selective tissue injury in part attributable to preferential localization of Verteporfin, administrated by intravenous infusion, to the choroidal neovascularization complex and irradiation of the complex with non-laser thermal light at 690 nm resulting in at least temporary thrombosis and vessel closure. Verteporfin is a benzoporphyrin derivative monoacid ring A formulated as a unilamellar liposome. In the blood Verteporfin is associated with lipoprotein fractions and is rapidly cleared via a receptor-mediated uptake mechanism due the high expression of LDL receptors in neovascular tissues. Verteporfin was undetectable in plasma 24 hr after infusion of the recommended dose: 6 mg/m2 of body surface area. The main side effect is photosensitivity of skin which is usually short-lived (24-48 hr) with a low incidence (2.3%). As skin photosensitivity depends on circulating rather than tissue drug levels, we investigate the possibility of developing a simple, fast and reliable spectrofluorometric method to measure plasma Verteporfin levels. Fluorescence emission spectrum (550-750 nm) of 1:10 saline diluted plasma with lambda exc=430 nm showed a characteristic emission peak at 692 nm, the height being proportional to the Verteporfin levels. The sensitivity is around 100 ng/ml and the pharmacokinetics of Verteporfin has been studied from 0 to 5 hr after infusion in six patients older than 65 years with age-related macular degeneration.
authors.affiliation: Université de la Méditéranée, Faculté de Médecine, Laboratoire de Biochimie et Biologie Moléculaire, 27 Boulevard Jean Moulin, 13385 Marseille, cedex 05, France. robert.aquaron@medecine.univ-mrs.fr
authors.forename: R
authors.initials: R
authors.lastname: Aquaron
authors.forename: O
authors.initials: O
authors.lastname: Forzano
authors.forename: J L
authors.initials: JL
authors.lastname: Murati
authors.forename: G
authors.initials: G
authors.lastname: Fayet
authors.forename: C
authors.initials: C
authors.lastname: Aquaron
authors.forename: B
authors.initials: B
authors.lastname: Ridings
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008027:Light; D008081:Liposomes / Q000378:metabolism; D008268:Macular Degeneration / Q000628:therapy; D008297:Male; D008956:Models, Chemical; D009389:Neovascularization, Pathologic; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics*; D011166:Porphyrins / Q000493:pharmacokinetics*; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013053:Spectrophotometry; D013997:Time Factors; D014466:Ultraviolet Rays; D000077362:Verteporfin
chemical_list: D008081:Liposomes; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin